AstraZeneca denies it is in discussions to fast-track U.S. approval of its COVID-19 vaccine
Pharmaceutical giant AstraZeneca (Tii:AZN) says it has held no discussions with the U.S. government about emergency authorization for the COVID-19 vaccine it is manufacturing. That vaccine is still undergoing late stage human clinical trials in several sites around the world, including in the U.K. and the U.S., making a rapid approval under the criteria the U.S. Food and Drug Administration has established so far a long shot.
Palantir takes aim at Silicon Valley in IPO filing
Palantir (Tii:PLTR), the data analytics company whose work on counter-terrorism has made it one of the Silicon Valley’s most controversial tech concerns, has sought to draw a clear line between its own business and what it dismissed as the “idiosyncrasies and excesses” of the rest of the valley, as it announced plans for a stock market listing.
Dick’s Sporting Goods crushes Wall Street estimates as online sales surge 194%
Dick’s Sporting Goods (Tii:DKS) reported eye-popping quarterly earnings and sales growth Wednesday, saying consumers flocked to its website for hiking gear, kayaks, weights and workout clothes to stay busy during the coronavirus crisis.
Facebook warns Apple’s iOS 14 could shave more than 50% from Audience Network revenue
Facebook (Tii:FB) on Wednesday acknowledged that Apple’s (Tii:AAPL) upcoming iOS 14 could lead to a more than 50% drop in its Audience Network advertising business. Facebook said its apps on iOS 14 will not collect IDFA, which is a unique device ID number that allows advertisers to better target ads and estimate their effectiveness.
Abbott wins U.S. authorization for $5 rapid COVID-19 antigen test
Abbott Laboratories (Tii:ABT) said on Wednesday it won U.S. marketing authorization for a COVID-19 portable antigen test that can deliver results within 15 minutes and will sell for $5. The portable test is about the size of a credit card, requires no additional equipment to operate, and can be conducted using a less invasive nasal swab than traditional lab tests, Abbott executives said on a call with reporters.
